close

Enter

Log in using OpenID

Global Dengue Vaccines Market Trends – 2024.pdf

embed
Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated wi
Artificial Pancreas Market Industry
Dengue Vaccines Market - Global Industry Insights,
Trends, and Opportunity Analysis, 2016-2024
[DATE]
[COMPANY NAME]
[Company address]
Report Description
Dengue Vaccines Market Outlook – Research Pipeline
There are approximately five vaccine candidates under evaluation in clinical trials, including other live attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. Also,
technological approaches, such as virus-vectored and VLP-based vaccines, are under evaluation in
preclinical studies. In September 2016, Takeda announced the beginning of the phase 3 clinical trials of
its dengue vaccine – TAK-003 vaccine. This vaccine is also aimed at prevention against all four dengue
virus strains.
Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and subtropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the
excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment
of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4).
Therefore, focus has been mainly on prevention by controlling the vectors being borne. Severe dengue
was discovered in the 1950s during dengue epidemics in Philippines and Thailand. The disease has since
spread to Asian and Latin America countries and is one of the leading causes of hospitalization and deaths
among children and adults in these regions.
Get free Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/23
Prevalent Scenario in the Global Dengue Vaccines Market
Member states in three of the WHO regions regularly report the annual number of dengue cases. These
statistic suggest that the number of dengue cases increased from 2.2 million in 2010 to 3.2 million in 2015.
The actual number remains underreported. One recent estimate by Bhatt et al., (also quoted by the WHO)
mentions that there are around 390 million dengue cases worldwide each year, with number of cases
reported increasing each year. In 2015, 2.35 million cases of dengue were reported in the Americas alone,
of which 10,200 cases were diagnosed as severe dengue that led to 1,181 deaths. Dengue is a pertinent
health issue affecting people across South America, Europe, and Asia. A large number of dengue
outbreaks were reported worldwide in 2015, with over 169,000 cases in the Philippines and over 111,000
suspected cases of dengue in Malaysia. This was a staggering 59.5% and 16% increase respectively in
the number of cases compared to that in 2014. The global dengue vaccines market therefore, offers
lucrative growht opportunities for vaccine manufacturers.
Dengvaxia – the only approved product in the global dengue vaccines market
Sanofi Pasteur’s Dengvaxia, is the culmination of over two decades of scientific innovation and
collaboration. The vaccine received its first marketing authorization in 2015, in Mexico. Dengvaxia is the
world’s first licensed vaccine for prevention of dengue. It is a tetravalent dengue vaccine that prevents the
disease from all four dengue viruses in people aged 9 to 45 years. Sanofi launched the world’s first public
dengue vaccination program in the Philippines (2016), followed by Brazil. Dengvaxia is approved in 10
endemic countries worldwide, namely, Singapore, Mexico, the Philippines, Paraguay, Brazil, El Salvador,
Costa Rica, Indonesia, Peru, and Guatemala. The global dengue vaccines market is thus, expected to
expand with growing market approvals.
Ask for Request Customization @ https://www.coherentmarketinsights.com/insight/requestcustomization/23
India is however taking a precautionary approach in approving this vaccine due to lack of studies among
the population in the country. A scientist in India has developed a dengue vacci ne that was successfully
tested in monkeys. If successful in human trials, this could be a breakthrough invention for prevention of
dengue among the populace in the country. Moreover, various philanthropists and global organizations
are investing in developing vaccines for malaria and dengue.
About Us
COMPANY OVERVIEW
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting
our plethora of clients achieve transformational growth by helping them make critical business decisions.
We are headquartered in India, having office at global financial capital in the U.S. Our client base includes
players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to
help businesses around the globe deliver practical and lasting results through various recommendations
about operational improvements, technologies, emerging market trends and new working methods. We
offer both customized and syndicated market research reports that help our clients create visionary growth
plans to provide traction to their business. We meticulously study emerging trends across various
industries at both the global and regional levels to identify new opportunities for our clientele. Our global
team of over 100 research analysts and freelance consultants provide market intelligence from the very
molecular country level and also provide a global perspective of the market. Our team is of the most vital
cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive
defusion training module.This allows for an objective and unbiased assessment of the market. We pride
ourselves in my constantly striving to update our extremely in-depth understanding of the market by
closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable
industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize
on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth
path in the future.
Contact Us
CORPORATE OFFICE:
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel No: (+1)206-701-6702
Email: [email protected]
Website: https://www.coherentmarketinsights.com/
Visit Blog: http://healthcaremarketconsulting.blogspot.in/
Author
dhiwarr07
dhiwarr0747   documents Email
1/--pages
Report inappropriate content